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Fibronectin binding protein F1 (Sfb1) of Streptococcus pyogenes (group A streptococcus [GAS]) is a well-
characterized adhesin that has been shown to induce protection in mice against a lethal intranasal GAS
challenge after intranasal immunization with cholera toxin B subunit (CTB) as adjuvant. With a murine skin
infection model, we have shown that Sfb1/CTB vaccination neither elicits opsonizing antibodies nor prevents
systemic bacterial growth and dissemination to internal organs after a subcutaneous GAS challenge. These
results indicate that an Sfb1-based vaccine should be complemented with additional protective antigens in
order to be used in areas such as the tropical north of Australia, where the skin is the primary route of entry
for invasive streptococcal diseases.
Among the aboriginal population living in the Northern
Territory of Australia (NT), the incidence and prevalence of
streptococcal infection and streptococcal diseases are high.
Unlike in Europe and the United States, where the throat is
often the primary tissue reservoir, the skin is the major site of
infection for the aboriginal population (12). Rates of group A
streptococcal (GAS) skin infection are extremely high, owing
in part to infection of scabies lesions, with pyoderma preva-
lence rates in children of up to 70% (13). The rate of strepto-
coccal invasive diseases among the aboriginal population is five
times that of the general population, with skin infections un-
derlying most cases (5). The incidence of poststreptococcal
sequelae is also high, with rates of acute rheumatic fever in
aboriginal populations among the highest reported and acute
glomerulonephritis being endemic in many regions (4). Ge-
netic typing of strains causing GAS infection in aboriginal
communities has demonstrated that the diversity and turnover
rate of these strains are much higher than those reported in
other regions and has revealed no evidence of a dominant
clone that has been a common cause of GAS invasive infec-
tions elsewhere in the world (3, 6). Vaccination might consti-
tute the most suitable strategy to control GAS infections in
these communities.
Bacterial adhesins have been proposed as potential vaccine
targets for the prevention of infectious diseases (36). In this re-
gard, Streptococcus pyogenes produces a number of MSCRAMMs
(microbial surface components recognizing adhesive matrix mol-
ecules) that are believed to mediate adhesion of the pathogen to
host tissue, a critical step in the initial stages of infection (27). A
number of GAS MSCRAMMs capable of binding fibronectin
have been identified, and they include protein F1/Sfb1 (16, 31),
28-kDa antigen (9), FBP54 (10), serum opacity factor (21, 28),
protein F2 (18), PFBP (29), FbaA (33), FbaB (34), and SfbX (19).
This diversity of fibronectin binding proteins suggests both the
importance of fibronectin binding in the pathogenesis of GAS
infection and the possibility that these proteins are differentially
expressed at different stages of the infection process (17).
GAS fibronectin binding proteins have been suggested as
potential vaccine targets for preventing GAS infections (7).
Antibodies directed against such adhesins may prevent bacte-
rial attachment and inhibit colonization (36). Sfb1 is a well-
characterized fibronectin binding protein of GAS and is be-
lieved to mediate bacterial attachment to host cells and
internalization of GAS into nonphagocytic cells (26, 31). Sfb1
has also been shown to interfere with host macrophage-medi-
ated clearance mechanisms by binding to the Fc fragment of
human immunoglobulins (24). When adjuvanted with cholera
toxin B subunit (CTB), intranasal immunization with Sfb1 in-
duces protection against an intranasal challenge with a lethal
dose of GAS (15). Vaccinated mice produce a strong immu-
noglobulin G (IgG) serum antibody response in a Th2-like
pattern (30). However, critical to this level of protection is the
elicitation of mucosal immunity in the lungs of vaccinated
mice. It is believed that this mucosal immune response may
prevent S. pyogenes from binding to the upper respiratory ep-
ithelium, thereby preventing colonization and establishment of
infection (36). Other characteristics that make Sfb1 an attrac-
tive vaccine candidate are the presence of highly conserved
epitopes and the fact that Sfb1 is expressed on the surface of
70% of clinical GAS isolates belonging to different serotypes
and strains, independent of geographic origin (14, 32, 35).
Anti-Sfb1 antibodies do not cross-react with heart proteins and
therefore may not trigger autoimmune reactions that might be
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responsible for poststreptococcal sequelae (35). Although vac-
cination with Sfb1 conferred protection against mucosal infec-
tion with S. pyogenes, the question remains whether it is also
protective against systemic spread subsequent to skin infec-
tions. The objective of this study was therefore to determine
whether the immune response generated against Sfb1 was able
to confer protection against a subcutaneous challenge with S.
pyogenes.
BALB/c mice were immunized by intranasal inoculation (10
l/nare) with a mixture containing 30 g of Sfb1 and 10 g of
CTB on days 1, 3, 5, and 15 as previously described (15). For
characterization of the immune response, serum samples, lung
washes, and spleen samples were collected 14 days after the
last booster immunization. Lung washes were obtained by tra-
cheal cannulation and gentle washing with 0.7 ml of cold phos-
phate-buffered saline (PBS) containing 2 mM phenylmethyl-
sulfonyl fluoride. To assess the generation of antigen-specific
effector cells by vaccination, lymphocytes were isolated from
the spleens of immunized mice and restimulated in vitro for 3
days in the presence of Sfb1 as previously described (25).
Results in Fig. 1A show that intranasal immunization with Sfb1
elicited a significant serum IgG antibody response to the vac-
cine antigen compared to that of nonvaccinated control mice
(P  0.029). As shown in Fig. 1B, immunization with Sfb1 also
elicited elevated antigen-specific IgA and IgG antibody re-
sponses in the lung on day 14 postvaccination. Spleen cells
isolated from mice vaccinated with Sfb1, compared with con-
trols, displayed elevated proliferative responses on day 14 post-
vaccination (Fig. 1C).
A previously described mouse skin infection model (23) was
then used to examine the capacity of the immune response
generated after vaccination with Sfb1 to restrain bacterial dis-
semination from the local infection foci at the skin. For this
purpose, groups of Sfb1-vaccinated and nonvaccinated control
mice were challenged with a subcutaneous injection containing
of S. pyogenes strain A20 (M type 23) (22) obtained from the
German Culture Collection (DSM 2071) at 106 CFU/100 l
administered into the back on day 14 postvaccination. At var-
ious times after infection, mice were sacrificed by CO2 asphyx-
iation, their livers and spleens were removed, and bacterial
loads were determined in homogenates of these organs after
serial dilutions were plated in blood agar.
The results presented in Fig. 2 show that both vaccinated
and nonvaccinated mice had comparable rates of systemic bac-
terial growth and dissemination. Vaccination with Sfb1 had no
effect on the growth of S. pyogenes in the blood of challenged
mice (Fig. 2A) and also failed to limit bacterial dissemination
and growth in both the spleen (Fig. 2B) and the liver (Fig. 2C)
in infected animals. By contrast, GAS extracts containing other
antigens were found to protect against systemic infection in
this animal model (E. Medina, personal communication), thus
validating this model system for such vaccination studies.
These results suggest that serum antibodies generated
against Sfb1 might be devoid of bactericidal activity against S.
pyogenes. To further demonstrate this assumption, a bacteri-
cidal assay was performed with serum from mice vaccinated
with either PBS, CTB, or CTB/Sfb1. Serum samples obtained
from mice immunized with pepsin-extracted M protein
(PepM) were used as a positive control for the opsonizing
assay. Serum samples were mixed with an inoculum of S. pyo-
genes A20 containing approximately 30 CFU and added to
heparinized fresh human blood obtained from a donor known
to be nonopsonic for this streptococcal strain. The mixture was
rotated for 3 h at 37°C, and the mean CFU count was deter-
FIG. 1. The immune response directed against Sfb1 at 14 days
postimmunization. (A) Specific IgG (solid bar) and IgA (unfilled bar)
present in the serum of control and vaccinated mice. Results are
expressed as the geometric means of five mice per group. The standard
error of the mean is indicated by vertical bars. (B) Specific antibodies
in lung washes of control and vaccinated mice. Results are expressed as
the percentage of Sfb1-specific antibodies with respect to the total
immunoglobulin isotype. The standard error of the mean is indicated
by vertical lines. (C) Sfb1-specific proliferative responses of spleen
cells. Results are expressed as the mean counts per minute of triplicate
samples for three or four mice per group. The standard error of the
mean is indicated by vertical lines. The results are statistically signifi-
cantly different from the values for control mice (*, P 0.05; Student’s
t test).











mined by plating dilutions on blood agar plates. As shown in
Fig. 3, serum samples from mice vaccinated with PBS, CTB, or
CTB/Sfb1 failed to inhibit bacterial growth while serum sam-
ples from mice immunized with the PepM extract totally in-
hibited the growth of S. pyogenes A20 (Fig. 3). The bactericidal
effect of rabbit polyclonal anti-Sfb1 serum samples was also
tested, and they failed to inhibit bacterial growth. However,
this antiserum was able to detect Sfb1 in Western blot assays
performed to confirm the expression of Sfb1 by S. pyogenes
A20 under the growth conditions used for opsonization (data
not shown).
As GAS produces a number of MSCRAMMs capable of bind-
ing to a variety of extracellular matrix components, including
fibronectin, it is likely that the expression of these proteins is
regulated in a coordinated manner during the infection process. It
is not known if Sfb1 is expressed during colonization of or inva-
sion through the skin. Protective immunity against GAS infection
is believed to be via two major mechanisms (11). (i) Bacteria can
be prevented from entering the host by blocking attachment and
colonization at mucosal surfaces, and (ii) once GAS has entered
host tissues, infection can be eliminated by opsonization with
specific antibody and complement, followed by phagocytosis. It
has been reported that immune responses against peptides based
on the conserved region of streptococcal M protein confer pro-
tective mucosal immunity against colonization but do not reduce
the rate of mortality due to systemic streptococcal infection and
are also nonopsonic (2). Similarly, while an IgA response against
Sfb1 will protect mice from an intranasal GAS challenge, this
study for the first time has shown that serum IgG against Sfb1 is
not opsonic and does not reduce the growth or dissemination of
GAS in a murine skin infection model. Other GAS fibronectin
binding MSCRAMMs, SOF and FBP54, have been shown to
elicit opsonizing antibodies and protect against a systemic intra-
peritoneal GAS challenge (8, 20). This suggests that GAS fi-
bronectin binding MSCRAMMs, and other potential GAS vac-
cine candidates, should be assessed with both intranasal and
systemic GAS infection models. Furthermore, it remains to be
determined whether the apparent lack of efficacy against a skin
challenge found in this study is also seen for other vaccine can-
didates that have looked promising in oral and nasal challenge
studies (1).
Despite the presence of high anti-Sfb1 titers in the serum of
vaccinated mice, GAS strain A20 was still able to grow and
disseminate at a rate comparable to that in naive mice. In the
NT, the most common focus of invasive infection is the skin
(5). In this population, high serum anti-Sfb1 titers are also seen
in both aboriginal controls and aboriginal patients with defined
FIG. 2. Clearance of S. pyogenes A20 from the blood, spleen, and
liver of mice after a subcutaneous challenge with 106 CFU. Results are
expressed as the mean CFU count determined for five mice per Sfb1-
vaccinated mouse group (solid line) and PBS-vaccinated control
mouse group (dashed line). The standard error of the mean is indi-
cated by vertical lines.
FIG. 3. Bactericidal effect of systemic antibodies against DSM2071.
Serum from mice intranasally vaccinated with PBS, CTB, or CTB/Sfb1
was mixed with an inoculum of DSM2071 containing approximately 30
CFU, added to heparinized human blood, and rotated for 3 h at 37°C.
The mean CFU count was determined by plating dilutions on blood
agar plates. Serum samples from mice immunized with pepsin-ex-
tracted M protein from DSM2071 (PepM) was used as a positive
control for the assay. The opsonic effect of rabbit polyclonal anti-Sfb1
serum was also assessed.











streptococcal infections (14), and yet this immune response
does not offer protection against systemic GAS infection. To-
gether these observations suggest that high anti-Sfb1 titers in
serum do not prevent dissemination of GAS into deeper tis-
sues from the skin. The results of this study appear to reflect
epidemiological observations in the NT, where skin infection
predisposes to severe GAS infection despite high IgG antibody
titers against Sfb1 in the population (14).
In summary, while an anti-Sfb1 immune response protects
against pharyngeal colonization (15, 30), this response is inad-
equate for protection against systemic infections as a conse-
quence of skin colonization. Thus, while Sfb1 may be a useful
vaccine candidate in regions where the throat is the primary
site of infection, this antigen may not fulfil such a role in
regions where the skin is the primary infection site.
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